Sandoz to acquire three established brands sold in more than 100 markets- Acquisition, including leading global brand Zinnat®, confirms
Sandoz commitment to antibiotics, following plans to expand its integrated manufacturing site in Kundl - Transaction complements
Sandoz leadership in generic penicillins with a leading position in cephalosporins – largest antibiotic segment by global sales
The agreement includes the global rights to three established brands (Zinnat®, Zinacef® and Fortum®)) in more than 100 markets. It excludes the rights in the US,
In line with its integrated manufacturing strategy,
“This important transaction will further position
“Cephalosporins are the largest antibiotic segment by global sales and acquiring this leading business, including the established global Zinnat® brand, will complement our #1 position in generic penicillins, the other key segment. It will also set us up for additional synergies driven by an increased promotional footprint that will support growth of both the acquired brands and the current existing
The agreement confirms the
Kundl is the hub and center of the last major integrated production chain for antibiotics in the western world. Its focus is on generic penicillin products, but the plant also produces finished dosage forms of several generic cephalosporin products.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plans,” “commitment,” “to acquire,” “to expand,” “expected,” “intends,” “expect,” “focus,” or similar terms, or by express or implied discussions regarding the agreement to acquire GSK’s cephalosporin antibiotics business; or regarding potential future revenues from Zinnat, Zinacef or Fortum. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the transaction described in this press release will be completed in the expected time frame, or at all. Neither is there any guarantee that the expected benefits or synergies from such transaction will be achived in the expected timeframe, or at all. Nor can there be any guarantee that Zinnat, Zinacef or Fortum will be commercially successful in the future. In particular, our expectations regarding the transaction described in this press release and Zinnat, Zinacef and Fortum could be affected by, among other things, the satisfaction of customary closing conditions including regulatory approvals; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit
About
LinkedIn: https://www.linkedin.com/company/sandoz/
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandozglobal
CEO
+49 174 244 9501 (mobile)
chris.lewis@sandoz.com
+1 973 714 8043
michelle.bauman@sandoz.com
Novartis Media Relations
E-mail: media.relations@novartis.com
+44 7966 118 652
richard.jarvis@novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central | |||
+41 61 324 7944 | +1 862 778 5052 | ||
Thomas Hungerbuehler | +41 61 324 8425 | ||
+41 61 324 7188 |
© OMX, source